Creatine

ApprovedSmall molecule

GSK

Creatine is one of 157 small molecule programs targeting Psychiatric Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

156

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psychiatric DisorderActive, not recruiting

StrokeActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

Breast CancerActive, not recruiting

Major Depressive DisorderActive, not recruiting

Angelman SyndromeActive, not recruiting

Psychiatric DisorderPhase 3

Active, not recruiting

StrokePhase 2

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Major Depressive DisorderApproved

Active, not recruiting

Angelman SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Creatine

GSK

Approved

1 2

Trodelvy

Gilead

Preclinical

37 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

Acupan

YYonsei University

Preclinical

1 5

Chantix

PPrism Pharmaceuticals

Preclinical

1 6

Aquasol E

NNational Eye Institute (NEI)

Paracetamol

1 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Recombinant Human Chorionic Gonadotropin

Merck & Co.

Preclinical

1 10

Tetracycline Hydrochloride

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Not yet recruiting

Breast Cancer

NCT07372144

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis3 trials

Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

Completed·NNazem Atassi·Phase 2·NCT01257581·60 enrolled

Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis

Completed·—·Phase 2·NCT00355576·86 enrolled

Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00005674

Resistance1 trial

Effects of Creatine Supplementation on Muscle Mass and Function Among Older Women Subjected to Resistance Training

Completed·UUniversity of Chile·Phase 3·NCT02188849·50 enrolled

Parkinson's Disease1 trial

NET-PD LS-1 Creatine in Parkinson's Disease

Terminated·UUniversity of Rochester·Phase 3·NCT00449865·1,741 enrolled

Major Depression1 trial

Creatine Augmentation in Veterans With SSRI-Resistant Major Depression

Withdrawn·UUniversity of Utah·Phase 4·NCT01175616

Huntington's Disease1 trial

Creatine Therapy for Huntington's Disease

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 1/2·NCT00026988·64 enrolled

6 more indications

Psychiatric Disorder1 trial

Creatine Treatment in Psychiatric Disorders

Completed·—·Phase 3·NCT00140192·12 enrolled

Breast Cancer1 trial

Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment

Not yet recruiting·DD'Or Institute for Research and Education·Phase 3·NCT07372144·227 enrolled

Stroke1 trial

National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial

Completed·UUniversity of Rochester·Phase 2·NCT00063193·195 enrolled

Major Depressive Disorder1 trial

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

Completed·PPerry Renshaw·Phase 4·NCT02134808·71 enrolled

Angelman syndrome1 trial

Dietary Supplements for the Treatment of Angelman Syndrome

Completed·UUniversity of California, San Diego·N/A·NCT00348933·90 enrolled

Cognitive Function1 trial

A Clinical Study to Investigate the Effects of Creatine Supplementation on Muscle Energetics and Cognitive Function in Young Healthy Male Athletes and an Ageing Population

Completed· GSK logo

GSK·Phase 1·NCT02058654·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Creatine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Creatine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Creatine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GSK

Creatine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Amyotrophic Lateral Sclerosis3 trials

Resistance1 trial

Parkinson's Disease1 trial

Major Depression1 trial

Huntington's Disease1 trial

Psychiatric Disorder1 trial

Breast Cancer1 trial

Stroke1 trial

Major Depressive Disorder1 trial

Angelman syndrome1 trial

Cognitive Function1 trial

References

Drug Info

Quick Facts

Related News